knowledge -WSS

knowledge

author：fashion 2025-10-02 20:48:07 - browse：71

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Biden’s NIH nominee is languishing in Congress

WSS

Ventyx halts psoriasis drug development after lackluster trial results

Readout Newsletter: Zepbound, Valneva's vaccine, and more

What health policies could hitch a ride on a spending bill?

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

Recent heat wave in the Mediterranean caused by climate change: Study

UnitedHealth sued over use of algorithm in Medicare Advantage plans

explore

knowledge

Wikipedia

Virginia high school admissions case could be legal follow

Biden’s NIH nominee is languishing in Congress

Bright Health sells Medicare Advantage business to Molina

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

23andMe had bad news about my health. I wish a person had delivered it

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare wants to send $9 billion to 340B hospitals

After affirmative action ruling, medical educators look to 'holistic review'

Biden targets hefty hospital 'facility fees' that often surprise patients

explore

White House drug czar issues call for 'recovery

FDA reorg will put new emphasis on investigations, sources say

Medical school prerequisites are outdated

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

Cancer diagnosis changes perspective doctor, former hospital CEO

The aspartame in Diet Coke probably isn’t giving you cancer

explore

leisure time

leisure time

Wikipedia